Tag Archives: MTC

PR Newswire

Global Healthcare Interoperability Market to Witness Nearly Two-fold Growth by 2024

Leave a comment

Data interoperability and data analytics are key contributors to global market revenue for healthcare interoperability, says Frost & Sullivan

SANTA CLARA, California, July 27, 2020 — Frost & Sullivan’s recent analysis, Global Healthcare Interoperability Market, Forecast to 2024, contends that interoperability has become a critical consideration for all health IT (HIT) applications. Countries where HIT interoperability standards are equally important and regulated are projected to drive the market, registering near-double-digit growth. The buoyant market for global healthcare interoperability is expected to grow at a compound annual growth rate (CAGR) of 13.8%, reaching $7.96 billion by 2024 from $4.17 billion in 2019.

Global Healthcare Interoperability Market to Witness Nearly Two-fold Growth by 2024
Global Healthcare Interoperability Market to Witness Nearly Two-fold Growth by 2024

For further information on this analysis, please visit: http://frost.ly/49u.

“With the advent of innovative delivery models and shifting focus on value-based care, the demand for interoperable systems will continue to grow,” said Koustav Chatterjee, Transformational Health Principal Analyst at Frost & Sullivan. “Additionally, the ability to achieve medical device connectivity across the care continuum will be critical. Real-time integration of accurate patient-generated data from connected apps and systems into a central command center platform that uses cognitive algorithms to automate care coordination and personalize intervention will be a key competitive advantage during and post-COVID-19.”

Chatterjee added: “From product segment perspectives, data interoperability and data analytics will primarily dominate the global healthcare data interoperability market. Both of these solution segments are expected to contribute more than 90% of the global market revenue throughout the study period. Further, application program interface (API) integration is the third-most important solution segment contributing to global market revenue, followed by data cleansing, data integration, and application integration.”

Globally, major government agencies are mandating healthcare stakeholders to comply with national healthcare data interoperability standards. This is resulting in higher adoption of HIT applications, thereby presenting immense growth opportunities for vendors involved in healthcare interoperability, including:

  • API Management: Vendors are encouraged to create API partnership platforms to achieve cross-continuum connectivity.
  • Data Management: Cloud or on-premise data centers comprise actionable healthcare intelligence, indicative of a past pattern of diseases, payment frauds, and operational inefficiencies.
  • Electronic Medical Record (EMR) Partnerships: Build the EMR interoperability consulting services business line.
  • Medical Device Partnerships: Utilize real-time assessment of patient-generated data by care episodes and patient population.
  • Health Information Exchange: Develop a central infrastructure to enable the delivery of actionable health data.

Global Healthcare Interoperability Market, Forecast to 2024, is the latest addition to Frost & Sullivan’s Transformational Health research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Global Healthcare Interoperability Market, 2019–2024

K418

Contact:
Mariana Fernandez
Corporate Communications
P: +1 (210) 348.1012
E: mariana.fernandez@frost.com 
https://www.frost.com

Photo – https://mma.prnasia.com/media2/1219817/interoperability_healthcare.jpg?p=medium600

Related Links :

http://www.frost.com

PR Newswire

K-BioMed Pioneer: VUNO Med®-Fundus AI™ Becomes Korea’s First-ever Innovative Medical Device

Leave a comment

SEOUL, South Korea, July 27, 2020 — VUNO Inc., South Korean artificial intelligence (AI) developer and a member company of the Born2Global Centre, announced that VUNO Med®-Fundus AI™, its AI-based screening solution for the fundus, gained the honor of being the first-ever Innovative Medical Device in Korea by the Ministry of Food and Drug Safety (MFDS) in recognition of its high level of technological innovation. VUNO has proved its technological excellence in retinal fundus imaging analysis.

The MFDS was unanimously elected to be the first chair of Artificial Intelligence Medical Devices (AIMDs) at the International Medical Device Regulators Forum (IMDRF) held on June 25. All the credit goes to the agency’s continuous effort to set the path for the leading regulatory framework of AI-based medical devices by establishing guidelines for approval and review of AI-based medical devices in 2017 for the first time in the world.

With the MFDS taking at the helm, the Innovative Medical Devices are classified and designated among candidates that excel in safety and effectiveness compared to conventional medical apparatuses and treatments. The following is included in the evaluation criteria: technological intensity and pace of technological innovation (technological innovation); enhancement in safety and effectiveness compared to the existing medical devices (performance); and economic, social, and technological ripple effect (contribution to the public good and industrial value).

About VUNO Med®-Fundus AI™

VUNO Med®-Fundus AI™ analyzes retinal fundus images to detect more than 12 lesions and classifies them for diagnosis. The 12 findings detected by the device are an all–encompassing set of medical information that is crucial to diagnosing a wide range of retinal diseases including diabetic retinopathy, macular degeneration and glaucoma.

VUNO Med®-Fundus AI™ ranked top in the Automatic Detection Challenge on Age-related Macular Degeneration at the International Symposium on Biomedical Imaging (ISBI) 2020, following the winning of the Diabetic Retinopathy – Segmentation and Grading Challenge at the same competition in 2018 and the Medical Image Computing and Computer Assisted Intervention (MICCAI) 2018 Retinal Fundus Glaucoma Challenge. In addition, a clinical research paper published in Ophthalmology, one of the most prestigious academic journals in the field, validated the solution’s remarkable detection performance.

VUNO Med®-Fundus AI™, was approved as a Class III medical device in April by the MFDS based on the solution’s proven effectiveness and performance through a series of clinical trials. Furthermore, in June, it gained the Class IIa CE marking according to the European Union (EU) framework, thus allowing VUNO Med®-Fundus AI™ to be commercially launched in 27 EU member states and others that recognize the European CE mark.

For more detailed information on VUNO, please visit https://www.vuno.co/.

Media Contact

Yerim Kim
PR Manager, VUNO lnc.
rim@vuno.co

Sora Kang
PR Manager, VUNO Inc.
sora.kang@vuno.co

Jina Lee
PR Manager, Born2Global Centre
jlee@born2global.com

Related Links :

http://www.born2global.com/

PR Newswire

FUJIFILM Sonosite Launches New Point-Of-Care Ultrasound System With Adaptable Form Factor, Embedded Workflow, And The Most Advanced Image Clarity Sonosite Has Ever Offered

Leave a comment

BROOKVALE, New South Wales, July 24, 2020 — FUJIFILM Sonosite, Inc., specialists in developing cutting-edge point-of-care ultrasound (POCUS) solutions, and part of the larger Fujifilm Healthcare portfolio, has announced the launch of the new Sonosite PX ultrasound system. Sonosite PX is the next generation in Sonosite POCUS, with the most advanced image clarity ever seen in a Sonosite system, a suite of workflow efficiency features, and an adaptable form factor. 

"Every aspect of Sonosite PX was designed specifically for the clinicians on the front lines of medicine. We designed Sonosite PX as a tool to help clinicians in all fields of medicine to treat patients more effectively where it matters most – at the point of care." said Rich Fabian, President and Chief Operating Officer of FUJIFILM Sonosite, Inc. "To optimize clinician ergonomics and improve efficiency, the system has an innovative and adaptable work surface that can be used in a horizontal or vertical position based on the situational needs of the exam. The exceptional image clarity is the result of a new proprietary imaging technology – seeing anatomy more clearly with Sonosite PX provides an unparalleled level of confidence for diagnostic and procedural applications."

As with all Sonosite POCUS systems, Sonosite PX is built to the legendary durability, reliability, and ease of use standards that clinicians around the world depend upon. The ultrasound system and the new family of transducers are drop-tested to one meter and the work surface is sealed to the edge for simplified cleaning and disinfection.  When mounted on the specialized stand, Sonosite PX has an adaptable work surface position for optimal clinician ergonomics while a small footprint and adjustable height allows for closer bedside access. Information essential to completing an exam including patient information, reports, and worksheets, is intuitively placed in one location, saving clinicians time and effort when navigating the ultrasound system user interface.

Diku Mandavia, MD, FACEP, FRCPC, Senior Vice President and Chief Medical Officer of FUJIFILM Sonosite, Inc. explained, "Clinicians are continually expanding their use of ultrasound. With Sonosite PX, they can use one ultrasound system for different workflows because it adapts to fit their diverse needs." The Sonosite PX user interface is simplified to show most-used controls, calculations, and annotations. Dr. Mandavia continued, "The system has two cardiac options that allow clinicians to choose between gathering targeted information about the heart to determine overall patient well-being, or investigate specific cardiac conditions with more comprehensive calculations that provide detailed analysis of the structure and function of the heart. This allows clinicians to select the cardiac exam type that best fits their individual workflow needs. Furthermore in keeping with our commitment to education, we have greatly expanded our 3D animation educational videos which are very important to new users. Sonosite PX has more than 100 onboard scan-along education tutorials; the most expansive library in any point-of-care system."

Recognizing the importance of efficient documentation to the electronic health record (EHR), Sonosite PX has been designed for onboard documentation of ultrasound findings at the bedside. Sonosite PX integrates seamlessly with the company’s Sonosite Synchronicity solution, a workflow manager for POCUS that supports seamless credentialing, quality assurance, and billing across departments and institutions.

Learn more about Sonosite PX by contacting your Sonosite sales representative, or visit https://showcase.sonosite.com/au.

About Fujifilm Sonosite

FUJIFILM Sonosite, Inc. is the innovator in bedside and point-of-care ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by a global distribution network in over 100 countries. Sonosite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, please visit www.sonosite.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

Logo – https://techent.tv/wp-content/uploads/2020/07/fujifilm-sonosite-launches-new-point-of-care-ultrasound-system-with-adaptable-form-factor-embedded-workflow-and-the-most-advanced-image-clarity-sonosite-has-ever-offered.jpg

 

Related Links :

https://www.sonosite.com

PR Newswire

VectraCor and GS GmbH (Corpuls) Form Licensing Agreement to Incorporate VectraCor’s 22-Lead ECG and CEB® (Cardiac Electrical Biomarker) Technology in Corpuls Defibrillators

Leave a comment

Both Companies Committed to Bringing the Best Cardiac Care to the Healthcare Workers and Patients that Need It

TOTOWA, New Jersey, July 17, 2020 — GS Elektromedizinische Geraete G. Stemple GmbH, marketing defibrillators under the corpuls brand, and VectraCor Inc., announced today that they have concluded a licensing agreement allowing corpuls to incorporate VectraCor’s cloud-based version of VectraCor’s derived 22-Lead ECG and CEB® (Cardiac Electrical Biomarker) technology into corpuls devices. This will help corpuls’ customers obtain a faster ECG and even more clinically important cardiac data while helping their patients in the most urgent medical situations. VectraCor currently has this technology integrated into their VectraplexECG System, used mainly in Emergency Departments, Urgent Cares and Doctor’s Offices. The VectraplexECG System has approval in the United States (FDA), Europe (CE Mark), Taiwan and Australia and is patented worldwide.

Dr. Christian Klimmer, CEO of corpuls said, “In 1991 corpuls was the first medical device company in the field of multi-parameter / defibrillators introducing the 12-lead ECG to the market. A little revolution back then, standard worldwide as of today. With the introduction of the 22-lead ECG and the CEB® together with VectraCor we will again set the new standard in diagnosing cardiovascular disease, in particular in EMS. We deeply believe that our customers are very interested in more advanced diagnostics regarding acute coronary syndromes especially if this doesn’t come with the price of more time on scene. This will hopefully enable a higher diagnostic accuracy, earlier treatment and an easier choice of the most appropriate hospital where the patient is transported to. For the receiving hospital to know exactly what to expect we have created the possibility to send all 22-Leads as well as the CEB® ahead as a pdf or, in even more detail as part of our corpuls.misson Telemedicine solution.” 

Brad S. Schreck, President & CEO of VectraCor Inc. said, “We are very excited about this partnership with corpuls and to begin to license our patented technology so it can get into the hands of more of the brave life-saving medical professionals that need it. The corpuls product line is used widely and highly respected throughout the world, so naturally, we feel like they are an ideal partner to showcase our technology. We are also very pleased that corpuls sees the important clinical benefit of deriving a full 22-lead ECG which gives the provider more clinically relevant views of the heart, right-sided, posterior, and vectorcardiogram which can have isolated issues when the 12-Lead ECG looks ‘normal’. The reduced electrode placement also saves money and patient prep-time along with helping avoiding potential electrode misplacement.” 

Schreck continued, “Our ECG technology may now help healthcare workers more quickly detect cardiac disease in real-time and non-invasively, in the form of VectraCor’s easy-to-read, color-coded, CEB® number. This could lead to a potentially faster treatment to save heart muscle and lives. After many years of published studies and presentations from prestigious institutions at medical congresses around the world such as ESC, ACC, ACEP, etc., which validated the clinical effectiveness of our technology, we are ready to take the company and healthcare to the next level. This will include licensing the CEB® and derivation technology and putting it into various multi-parameter monitors and other cardiac devices like stress tests, Holter/event monitors, mobile consumer devices and telemedicine platforms.”

On the strategic aspect of the partnership, Schreck said, “The defibrillator and EMS market has always been of major interest to us after VectraCor won the Top EMS Innovation Award at EMS World Expo a few years back. So partnering with corpuls, a major player in that market, fits right into our strategy and vision.” He added, “This is only the beginning in our fight against the number one disease state, and killer, in the world, cardiovascular disease.”  

About GS Elektromedizinische Geraete G. Stemple GmbH 
For close to 40 years, GS Elektromedizinische Geraete G. Stemple GmbH, a successful international family business, has been developing innovative medical devices for the emergency and intensive care medicine and manufacturers. Worldwide professional emergency services rely on the corpuls’ brand of robust and reliable medical products. For more information, visit www.corpuls.world  info@corpuls.com  +49 8191 657220 

About VectraCor Inc.
VectraCor is a medical device company based in Totowa, NJ focused in the cardio-pulmonary space. Their patented technologies, the CEB® (Cardiac Electrical Biomarker), and a derived 22-lead ECG technology using only 5 electrodes (V2 & limbs), has the potential to be the new standard of care in ECGs and cardiac monitoring worldwide.  VectraCor also produces a portable Orbit™ spirometer (lung function test) that is used widely by everyone from General Practitioners to Respiratory Therapists worldwide. For more information please visit VectraCor at www.VectraCor.com  Info@Vectracor.com  1.973.904.0444 ext. 2

Related Files

VectraCor Corpuls Press Release 7 14 2020 FINAL.pdf

Related Links :

http://www.VectraCor.com

PR Newswire

Mexico Telecommunication Giant, Alestra, Deploys Bright Pattern Contact Center Software for CENACED’s Telehealth Services During COVID-19

Leave a comment

Alestra, deploys Bright Pattern Contact Center for nonprofit, CENACED, to offer remote psychological teleassistance services during the pandemic

SOUTH SAN FRANCISCO, California, July 15, 2020 — CENACED, a non-profit healthcare organization, has deployed Bright Pattern as their cloud-based contact center software provider amid the COVID-19 pandemic. CENACED uses Bright Pattern to offer free telehealth services to help citizens in Mexico dealing with stress during the quarantine. They have also moved agents and counselors to a remote model to protect the safety of their employees during the pandemic.

VIDEO EMBEDDED: https://www.youtube.com/watch?v=XKZKmhY6KtQ&feature=youtu.be

A recent poll by the Kaiser Family Foundation found that the pandemic has negatively affected the mental health of 56 percent of adults. In April, texts to a US federal emergency mental-health line were up 1,000 percent from the year before. The situation is particularly dire for certain vulnerable groups—health-care workers, COVID-19 patients with severe cases, and people who have lost loved ones. CENACED is working with Bright Pattern, Alestra, and Bright Pattern partner, Call It Once, to bring telehealth counseling services to impacted people in Mexico to help people deal with the current health crisis.

CENACED offers free psychological telecare to people who have symptoms of stress derived from quarantine and with Bright Pattern’s virtual call center technology are now handling 120 cases per hour and serving almost 50,000 people per month. Alestra, Bright Pattern, and Call It Once joined CENACED in this critical initiative, enabling a teleassistance contact center in the cloud as shown in this video showing the solution in action. Per CENACED this cloud contact center was deployed in “record time” and is “a technology initiative that changes lives”:

“Bright Pattern has helped global companies during the pandemic by providing a 100% virtual platform allowing customers to seamlessly transition to remote teams,” said Michael McCloskey, CEO of Bright Pattern. “Countries in both Asia and Europe have also used Bright Pattern to help with COVID contact tracing but this is the first Bright Pattern powered contact center that is helping offer telehealth services during the pandemic as well.”

“Today, the world is facing challenging times. People and companies are taking the lead in collaborating in a more personalized way leveraging innovative technology,” said Ana Llano, Regional Manager, Latin America, Bright Pattern. “With our help, CENACED was able to deploy a hybrid contact center with onsite and remote agents quickly thanks to the ease-of-use of the Bright Pattern platform. Agents were ready to provide personalized virtual counseling services and psychological teleassistance to Mexican citizens during the COVID-19 pandemic. At Bright Pattern, we are proud to collaborate with our partners and help CENACED with this innovative use of technology focused on helping people and keeping agents safe at home.”

Bright Pattern Virtual Call Center
Bright Pattern’s cloud-based virtual call center solution for remote agents delivers all of the benefits of a traditional contact center solution while providing the additional benefits of the flexibility gained through the use of remote workers. Our virtual contact center software solution allows your organization to “flex” during peak or low times, recruit talent from any geography, and deliver a complete omnichannel customer experience. In addition, Bright Pattern provides a powerful omnichannel quality management solution that allows you to score 100% of all customer interactions and manage agent performance to better manage remote workers. This combination of advanced omnichannel virtual contact center software with embedded quality management makes Bright Pattern the clear choice for delivering the best customer and agent experience.

Bright Pattern Cloud Contact Center Features:

  • Business Continuity – Keep your business going no matter what interruptions local offices or business settings face. Bright Pattern has a robust system designed to ensure uninterrupted continuity in the case of a local disaster or facility interruption.
  • Scalability – Bright Pattern cloud call center software allows you to easily supplement your existing workforce with additional remote agents in minimal time.
  • Deploy in Days – Bright Pattern was rated by G2 Crowd for quickest time to deploy out of all CCaaS vendors in the industry with the highest ROI and ROI payback time. Bright Pattern Cloud Contact Center can be deployed in days instead of the weeks it takes most CCaaS vendors.
  • Geographic flexibility – allow agents to access the exact same information that they would typically access in their offices from anywhere with a stable internet connection.
  • Maintain voice quality across geographies – Bright Pattern’s Automatic Call Distribution (ACD) software routes callers to the optimal agent.
  • Built in Quality Assurance – Monitor 100% of interactions regardless of channel with AI-powered quality management with sentiment and speech analytics for automated quality assurance in real-time across the globe.
  • Data Privacy – Fully compliant with international regulations including PCI DSS, HIPAA, DGPR, TCPA, and SOC.

If you are experiencing a spike in calls as a result of the outbreak or need to deploy a remote workforce, Bright Pattern is prepared to deliver consultations and cloud services to existing and new customers. Please contact us at marketing@brightpattern.com, call 925-548-0532, or request a demo.

Additional Resources:

About Bright Pattern
Bright Pattern provides the simplest and most powerful AI-powered omnichannel contact center software for innovative midsize and enterprise companies. With the purpose of making customer service brighter, easier, and faster than ever before, Bright Pattern offers the only true omnichannel cloud platform with embedded AI that can be deployed quickly and nimbly by business users—without costly professional services. Bright Pattern allows companies to offer an effortless and personal customer experience across channels like voice, text, chat, email, video, messengers, and bots. Bright Pattern also allows companies to measure and act on every interaction on every channel via embedded AI omnichannel quality management. The company was founded by a team of industry veterans who pioneered the leading contact center solutions and today are delivering an architecture for the future with an advanced cloud-first approach. Bright Pattern’s cloud contact center solution is used globally in over 26 countries and 12 languages.

About Alestra
Alestra is a Mexican IT Services company headquartered in San Pedro Garza García, in Greater Monterrey, Mexico.It is a subsidiary of the Mexican conglomerate Alfa and provides IT solutions for the corporate sector in Mexico. Alestra reported revenues of $415 million for 2014.

About CENACED
CENACED is a non-profit, plural, autonomous, and inclusive civil society organization, with no political or religious aims and always open to anyone who wants to join efforts to improve the living conditions of the population in vulnerable conditions. CENACED is dedicated to  promoting and strengthening a greater culture of prevention, health self-care, and self-protection in cases of disasters and epidemiological contingencies.

About Call IT Once
Call IT Once is made up of highly experienced professionals for contact center management and the continuous improvement of contact center processes and strategies.

Logo – https://techent.tv/wp-content/uploads/2020/07/mexico-telecommunication-giant-alestra-deploys-bright-pattern-contact-center-software-for-cenaceds-telehealth-services-during-covid-19.jpg

Related Links :

http://www.brightpattern.com
PR Newswire

Vela Diagnostics receives CE-IVD approval and Provisional Authorisation from the Health Sciences Authority in Singapore for automated COVID-19 detection test

Leave a comment

SINGAPORE, July 13, 2020 — Vela Diagnostics announced today that an automated version of its COVID-19 detection test, the ViroKey™ SARS-CoV-2 RT-PCR Test v2.0, has received the CE mark for in vitro diagnostic use as well as Provisional Authorisation from the Health Sciences Authority in Singapore.

The ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 is a probe-based reverse transcription PCR Test that detects SARS-CoV-2 by targeting conserved regions of the SARS-CoV-2 genome, specifically the ORF1a and N genes. The automated test is optimized for a workflow consisting of the Sentosa™ SX101 instrument, in conjunction with the Sentosa™ SA201 instrument or the ABI 7500 Fast Dx. The automated workflow enables high throughput testing with significantly reduced hands-on time. Up to 48 tests, including controls, can be performed in a single run. “Receiving CE certification and Provisional Authorisation from the Health Sciences Authority in Singapore for our automated test facilitates efficient testing of SARS-CoV-2 in patients suspected of COVID-19 in Europe, Africa, Middle East and Asia, where there is an urgent need to identify individuals infected with SARS-CoV-2 for effective management of the global pandemic,” said Managing Director, Andreas Goertz.

In April this year, an earlier version of the test, the ViroKey™ SARS-CoV-2 RT-PCR Test, also received the CE mark and Provisional Authorisation from the Health Sciences Authority in Singapore.

About Vela Diagnostics

Vela Diagnostics is a leading provider for integrated IVD system solutions, from sample to result. VELA’s test solutions utilize the automated Sentosa™ platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.

All Sentosa™ products listed above are by Vela Diagnostics. For more information, visit www.veladx.com.

Related Links :

http://www.veladx.com

PR Newswire

United Imaging Announces New Technology That Advances Molecular Imaging, Hints at a Series of New Announcements

Leave a comment

Company is sponsoring its second SNMMI Annual Meeting.

HOUSTON, July 11, 2020 — United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, continues to set a new standard in molecular imaging and redefine nuclear medicine. The company has begun unveiling new technology that showcases more of its all-digital platform and its significant commitment to U.S. market growth. United Imaging will host a virtual booth at the 2020 SNMMI Annual Meeting and will meet with customers in that environment and through its own virtual meeting technology.

“United Imaging is taking a unique look at this industry,” said Jeffrey M. Bundy, Ph.D., CEO, United Imaging Healthcare Solutions in the U.S. “We built a company that from the ground up is designed for modern solutions, to address needs American healthcare providers wanted addressed. In just one short year since the last SNMMI meeting, we’ve moved fast. I think when people chat with us this year, although there is no in-person conference to physically see and touch our booth, they’ll learn that we’ve done exactly what we set out to do.”

For SNMMI, United Imaging announced that HYPER Iterative functionality is FDA cleared for its uMI 550 digital positron emission tomography (PET) / computed tomography (CT) scanner. This solidifies the company’s commitment to address the needs of the American patient. HYPER Iterative can achieve high image contrast and quantification accuracy while giving users the flexibility to reduce scan times and improve patient comfort.

In addition, United Imaging was the first in the U.S. to launch a mobile digital PET/CT unit, which will dramatically improve patient access to state-of-the-art imaging tests, including digital technology that was only available previously in fixed locations, and predominantly in large institutions or academic settings. The uMI 550 mobile scanner will hit the road to perform clinical scans this summer.

“This first-ever mobile digital PET/CT unit dramatically changes the game and makes research-level technology accessible to more people,” said Cheri Gottke, vice president of United Imaging’s molecular imaging portfolio in the U.S. “United Imaging has been leading in terms of achieving access, making this valuable — now mobile — digital PET/CT technology available to providers and patients in urban, suburban, and rural regions alike.”

Artificial intelligence (AI) remains the focus of substantial investment by the company. United Imaging also has announced the introduction of uAI technologies into key radiology systems with HYPER Deep Learning Reconstruction* in the routine PET/CT workflow of its uMI 550 and uMI 780 digital PET/CT systems to enhance image quality.

United Imaging also announced that more than 3,500 clinical patients have been scanned on its uEXPLORER® total-body PET/CT system. The average patient clinical total-body scan time is 1-3 minutes.

United Imaging developed uEXPLORER in partnership with the EXPLORER Consortium led by Simon Cherry, Ph.D., and Ramsey Badawi, Ph.D., from the University of California, Davis. The two were recently honored for that achievement with a 2020 Innovator of the Year Award from their university. uEXPLORER also received a Gold Award and a Silver Award in the 2020 American Business Awards.

“The core uEXPLORER technology is actually embedded in every product in our MI portfolio,” said Gottke. “Also, the MI portfolio — and in fact all of our modalities — features what we call our ‘all-in’ approach, meaning that our systems ship with every feature already included, so customers can simply implement them as their needs change.”

Learn more about United Imaging’s presence at SNMMI here.

* Pending 510(k), not available for sale in the United States.

ABOUT UNITED IMAGING

At United Imaging, we develop and produce advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our U.S. R&D facility opened in 2013 in Houston and was further established as the U.S. headquarters in 2018 with our service team and commercial organization in place. With a cutting-edge digital portfolio and a mission of broader access to healthcare for all, we help drive industry progress and bold change.

To learn more, visit united-imaging.com or follow us on LinkedIn and Twitter @UnitedImagingHC.

Related Links :

http://www.united-imaging.com

PR Newswire

Carromex Unveils Pharma Leads, a Groundbreaking Cloud-based Platform for Rapid Drug Analysis and Discovery

Leave a comment

Mathematical Breakthrough by Australia-based Research Team Leads to a Shortening of Drug Discovery Times and Efficacy Analysis

SYDNEY and MELBOURNE, Australia, July 10, 2020 — Carromex, a mathematical research-based innovation company based in Australia, unveiled a new cloud-based pharmaceutical software platform called Pharma Leads https://carromex.com/products/pharma-leads/, that is set to significantly contribute to the advancement of the healthcare and pharmaceutical industry today. 

The platform provides pharmaceutical companies and researchers with two unique benefits: 

  • First, users can discover potential treatments by merely inputting the genetic sequence of the disease, dramatically reducing the time and costs associated with searching for new treatments.
  • Second, researchers and pharmaceutical companies can rapidly assess the safety and efficacy of the therapy by analyzing its genetic makeup to test if the combination will be harmful to the body.

The discovery was first made by Dr Burzin Bhavnagri while in pursuit of his Ph. D. at the University of Adelaide and is now available publicly for the first time. 

"Representational Consistency is an exciting and entirely new field of mathematics. In my thesis on the development of "Computer Vision using Shape Spaces" and my desire to apply the theory to a real-world example of cancer drug treatment, I discovered a formula which led to the creation of Pharma Leads", said Dr. Burzin.

From the Search for a Cure for Cancer to a Healthcare Breakthrough

In 2012, using his discovery of Representational Consistency, Dr Burzin began to research the 30 known definite carcinogens listed by the International Agency of Cancer Research (IARC), where he discovered a link between representational inconsistency and carcinogens, prompting the search for a cancer treatment using the theory. 

Dr Burzin then discovered that the same process could be used to dramatically reduce the research time and costs associated with drug development and discovery, leading to the creation of the Pharma Leads platform. 

Using Computer Vision to Revolutionize the Pharmaceutical Industry

Pharma Leads by Carromex is an interactive online program that works in silico without the need for a database which can systematically analyze a chemical structure or gene sequence. 

The revolutionary platform allows users to access a list of amino acids for a protein sequence or a list of nucleic acids for a gene sequence. The user can also enter the name of the medicines or their chemical structure to analyze a drugs safety and efficacy. 

"Users can choose from searching for a treatment or analyze how a chemical compound may interact with RNA or DNA, for instance, Acetaminophen," Dr Burzin explained further. 

Pharma Leads by Carromex is currently available on Google Cloud for users in the United States. 

For more information, please visit https://carromex.com/products/pharma-leads/ 

About Carromex and the Invention of Pharma leads 

Carromex was founded in the 1980s by the late Dr Nina Bhavnagri and her son Dr Burzin Bhavnagri. For the last eight years, the company has been focusing on mathematical research and program design. 

Related Links :

http://www.carromex.com

PR Newswire

WuXi AppTec to Launch a Special Webinar on Collaborations that Transform on July 16 | Advances in Rare Diseases: Hemophilia

Leave a comment

SHANGHAI and SAN DIEGO, July 9, 2020 — WuXi AppTec is pleased to announce that they are about to launch the second session of the webinar series “Collaborations That Transform,” highlighting the impact of partnerships in bringing effective therapies to patients. This complimentary webinar, to be broadcast worldwide on July 16, will convene leading physicians, drug developers, patients and advocates. These experts will discuss the latest advances in the development of transformative medicines for hemophilia, including gene therapy and next generation technologies.

As an enabler of the biotech and medical device industry, WuXi AppTec shares the conviction that we must work collaboratively to solve industry-wide problems and bring transformational medicines to people living with rare diseases. On July 16, the webinar will continue the dynamic discussions that began with WuXi AppTec’s inaugural rare disease webinar in May. It is complimentary and open to the public.

WuXi AppTec welcomes all to join the conversation.

Register Now: https://www.eventbrite.com/e/collaborations-that-transform-advances-in-rare-diseases-hemophilia-tickets-112318908880?aff=Content 

AGENDA (Eastern Daylight Time).

10:30 Welcome

10:35 – 11:00 Addressing the Unknowns in an Era of Transformations

  • A conversation with Glenn Pierce, VP Medical, World Federation of Hemophilia, Entrepreneur-in-Residence at Third Rock Ventures, and Chief Medical Officer at Ambys Medicines; moderated by Hui Cai, VP and Head of Content Division, WuXi AppTec

11:00 – 12:00 The Quest for Transformative Medicines

  • Federico Mingozzi, Chief Scientific Officer, Spark Therapeutics
  • John Pasi, Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
  • Richard Pezzillo, Executive Director, New England Hemophilia Association
  • Glenn Pierce, VP Medical, World Federation of Hemophilia
  • Rogerio Vivaldi, President & Chief Executive Officer, Sigilon Therapeutics
  • Guy Young, Director, Hemostasis and Thrombosis, Children’s Hospital Los Angeles; Professor of Pediatrics, University of Southern California Keck School of Medicine
  • Moderated by Richard Soll, Head of WuXi AppTec’s Boston office; Senior Advisor of Strategic Initiatives

12:00 Closing

Related Links :

http://www.wuxiapptec.com

PR Newswire

Paige Applauded by Frost & Sullivan for its Leading AI-based Computational Pathology Offering that Enables Fast and Accurate Cancer Diagnoses

Leave a comment

Paige leveraged the world’s largest dataset in pathology to develop an unparalleled computation pathology offering

SANTA CLARA, California, July 8, 2020 — Based on its recent analysis of the North American AI-based digital pathology market, Frost & Sullivan recognizes Paige with the 2020 North American Enabling Technology Leadership Award for its disruptive product offering.

Paige
Paige

Paige has developed robust machine learning models for computational pathology for detecting cancer subtypes, thereby enhancing the diagnosis capability of pathologists worldwide. Paige’s AI-based technology was developed and tested on over 100,000 de-identified, digitized slide images from more than 16,000 cancer patients. The deep learning algorithms detected prostate cancer, skin cancer, and breast cancer with near-perfect accuracy.   

“Paige’s AI algorithms validated against the world’s largest dataset in pathology makes it the most trustworthy best in class pathology diagnosis solution,” said Debarati Sengupta, Industry Analyst, Frost & Sullivan. “Paige’s technology eliminates the need to curate datasets, which is time-consuming and expensive. Paige’s AI based pathology offering enables pathologists to make a fast and accurate diagnosis of even the most complex and difficult to interpret slides.”

The Paige offering consists of general and organ-specific products that provide rapid diagnostic stratification, cancer detection, tumor segmentation, and prediction of treatment response, and overall survival. Its algorithms form a portfolio of AI-based digital diagnostics and biomarkers to help pathologists provide diagnoses. For security purposes, all datasets used to build the products were de-identified, and any protected health information or label text was removed.

Notably, Paige’s computational pathology offering received the Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2019, making it the first such device for cancer diagnosis. Furthermore, it began commercializing in 2019 following its CE mark approval for Paige Prostate, which is a first-to-market prostate cancer detection solution, and a digital pathology viewer for the primary diagnosis of any digital slide. Paige’s AI-based solutions are vendor agnostic, which helps it serve a wider pool of customers.

In 2020, it formed a strategic partnership with Invicro LLC, a Konica Minolta company to provide its AI-based integrated pathology solutions to support Invicro’s drug discovery and development initiatives. “Paige continues to expand its footprint not just in commercial laboratories, but also in biopharmaceutical companies, positioning itself as a pioneer in AI-based digital pathology market” noted Sengupta.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of new products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Kristen Moore
P: 210.247.3823
E: kristen.moore@frost.com

About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center.  The Company builds computational pathology products designed so patients and their care teams can make faster, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity.  Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, minimize IT burden and costs while ensuring patient safety and data privacy. Our products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first and only company to receive FDA breakthrough designation for computational pathology products.

For additional information, please visit:  https://www.Paige.ai  Twitter and LinkedIn

Media Contact:
NRPR Group
Nicole Rodrigues
(650) 815-5069
nicole@nrprgroup.com

Related Links :

http://www.frost.com